The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Rahma, Osama E ^a,d   Hamilton, J M ^a   Wojtowicz, Malgorzata ^a   Dakheel, Omar ^a   Bernstein, Sarah ^b   Liewehr, David J ^a   Steinberg, Seth M ^a   Khleif, Samir N ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

GM CSF; IL 2; Immune response; Peptide; Ras; Vaccine

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MUTANT PROTEIN; MUTANT RAS PEPTIDE VACCINE; RAS PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BILE DUCT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEASIBILITY STUDY; FEVER; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IN VITRO STUDY; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG CANCER; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYALGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PROGRESSION FREE SURVIVAL; RASH; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE; VOMITING;

ADULT; AGED; AMINO ACID SEQUENCE; CANCER VACCINES; ENZYME-LINKED IMMUNOSPOT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY; INTERLEUKIN-2; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASMS; RAS PROTEINS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84895177468     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-55     Document Type: Article

References (36)

1. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011, 2:344-358. 10.1177/1947601911411084, 3128640, 21779504.
2. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465. 10.1038/nrc1097, 12778136.
3. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982, 300:149-152. 10.1038/300149a0, 7133135.
4. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
5. Kiaris H, Spandidos D. Mutations of ras genes in human tumors (review). Int J Oncol 1995, 7:413-421.
6. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993, 143:545-554. 1887038, 8342602.
7. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011, 50:307-312. 10.1002/gcc.20854, 21305640.
8. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ, Bos JL, Rodenhuis S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990, 323:561-565. 10.1056/NEJM199008303230902, 2199829.
9. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991, 353:326-329. 10.1038/353326a0, 1922338.
10. Weiss S, Bogen B. MHC class II-restricted presentation of intracellular antigen. Cell 1991, 64:767-776. 10.1016/0092-8674(91)90506-T, 1847667.
11. Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 1997, 182:137-151. 10.1006/cimm.1997.1224, 9514698.
12. Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999, 22:155-165. 10.1097/00002371-199903000-00007, 10093040.
13. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001, 92:441-450. 10.1002/ijc.1205, 11291084.
14. Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol: Off J Am Soc Clin Oncol 2005, 23:5099-5107.
15. Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008, 57:1413-1420. 10.1007/s00262-008-0477-6, 18297281.
16. Zhang J, Scordi I, Smyth MJ, Lichtenheld MG. Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med 1999, 190:1297-1308. 10.1084/jem.190.9.1297, 2195674, 10544201.
17. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem 2010, 17:3297-3302.
18. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012, 61(3):373-384. 10.1007/s00262-011-1100-9, 3708463, 21927947.
19. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-327. 10.1038/nm0398-321, 2064864, 9500606.
20. Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 2004, 90:773-780. 10.1038/sj.bjc.6601563, 2410164, 14970852.
21. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996, 88:202-210.
22. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003, 97:186-200. 10.1002/cncr.11045, 12491520.
23. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90:3539-3543. 10.1073/pnas.90.8.3539, 46336, 8097319.
24. Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA, Khleif SN. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007, 25:5882-5891. 10.1016/j.vaccine.2007.05.040, 17602804.
25. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in r x c contingency Tables. J Am Stat Assoc 1983, 78:427-434.
26. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl T, Stokke KT, Sølheim BG, Egge TS, Søreide O, Thorsby E, Gaudernack G. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996, 65:450-453. 10.1002/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E, 8621226.
27. Meyer RG, Korn S, Micke P, Becker K, Huber C, Wolfel T, Buhl R. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer 2007, 58:88-94. 10.1016/j.lungcan.2007.05.003, 17599645.
28. Hunger RE, Brand CU, Streit M, Eriksen JA, Gjertsen MK, Saeterdal I, Braathen LR, Gaudernack G. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol 2001, 10:161-167. 10.1034/j.1600-0625.2001.010003161.x, 11380611.
29. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011, 60:433-442. 10.1007/s00262-010-0960-8, 21221967.
30. Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H, Chaput N, Barrou B, Thioun N, Gattegnio B, Selles F, Six A, Azar N, Lotz JP, Buzyn A, Sibony M, Delcourt A, Boyer O, Herson S, Klatzmann D, Lacave R. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 2009, 35:569-581.
31. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, Eastern Cooperative Oncology Group Study E3200 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol: Off J Am Soc Clin Oncol 2007, 25:1539-1544. Eastern Cooperative Oncology Group Study E3200.
32. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res: Off J Am Assoc Cancer Res 2011, 17:907-917.
33. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624, 19934295.
34. FDA Guidance for Industry Clinical Considerations for Therapeutic Cancer Vaccines 2011, FDA, http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf, FDA.
35. Slingluff CL, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol: Off J Am Soc Clin Oncol 2008, 26:4973-4980.
36. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res: Off J Am Assoc Cancer Res 2009, 15:1443-1451.